DoH Guidelines: Prophylaxis
[Treatment] [Prophylaxis]

 

COMMENTS ON DRUGS USED FOR CHEMOPROPHYLAXIS

Since antimalarial drugs may cause some  side-effects, the seriousness of any side-effect should be weighed up against the risk and  seriousness of contracting malaria. In most cases it is advisable to continue taking the  drug.

CHLOROQUINE

Chloroquine is relatively cheap and available without a prescription.  It can be safely used during pregnancy, lactation and in young children. Chloroquine  should be used with caution in patients with epilepsy, cardiac or renal disease.

It is usually well tolerated, with most side effects being mild and  reversible. The side-effects8 include:

    * headache

    * nausea, vomiting (reduced if taken with a meal)

    * diarrhoea

    * pruritus

    * skin eruptions and itching of the palms, soles of the feet and scalp

    * impaired vision

Serious side-effects are rare but may occur wth long term use.  Periodic eye examinations are recommended if chloroquine is used for extended periods.

PROGUANIL

It is considered to be one of the best tolerated antimalarial  drugs. It has a very good safety profile and can be used during pregnancy and for  children. Proguanil rarely causes side effects when used in prophylactic doses. Reported  side effects9 include:

    * mild gastric intolerance, which usually subsides as treatment is  continued

    * vomiting and abdominal discomfort

    * mouth ulcers

    * skin reactions

    * hair loss

 

MEFLOQUINE

Mefloquine should not be used for longer than 1 year at a time. The  following people should not take mefloquine:

    * pregnant women or for 3 months before conception

    * children weighing under 15 kg

    * patients with a history of epilepsy or psychiatric disorders

    * people with seizure disorders

    * people with cardiac conduction abnormalities

    * people with depression

    * people requiring fine coordination such as pilots, scuba divers,  mountaineers (it may interfere with fine motor-coordination)

    * patients on beta blockers, calcium channel blockers, digitalis or on  cyclic antidepressant therapy.

The following side-effects10 may occur when taking  mefloquine:

    * dizziness or disturbance of balance

    * gastro-intestinal disturbances

Less frequent side-effects10 that have been reported are:

    * headache, myalgia, feeling of weakness, visual disturbances

    * palpitations, bradycardia, irregular pulse and extrasystoles,  AV-block

    * hair loss, rash or pruritis, urticaria

    * convulsions

    * psychological changes, e.g. depressive mood, confusion, anxiety,  hallucinations, paranoid reactions

    * transient elevation of transaminases

    * leukopenia or leukocytosis and decrease of platelets

If signs of unexplained anxiety, depression, restlessness or confusion  are noticed, these may be considered prodromal to convulsions and the drug must be  stopped.

Travellers taking mefloquine, who find continued side effects  unacceptable, should switch to either chloroquine plus proguanil or doxycycline and not  take mefloquine again. If mefloquine is used for prophylaxis, halofantrine should not be  used for treatment since it may lead to potentially fatal prolongation of the QTC  interval.

DOXYCYCLINE

Doxycycline is usually well tolerated and the most common adverse  effects11 are:

    * gastro-intestinal disturbances such as nausea and diarrhoea

    * photosensitivity (characterised by an exaggerated sunburn reaction)

    * various dermatological reactions

    * vaginal candidiasis

Doxycycline is contraindicated during pregnancy, in breast-feeding  mothers and in children under 8 years of age, as it can seriously damage tooth  development. Doxycycline is not recommended for longer than 3 months (due to lack of  safety data for long-term use of daily 100 mg administration). It is an option to consider  for epileptic patients who have to enter a high-risk chloroquine-resistant malaria area.

 The  guidelines are endorsed by the Medical Association of South Africa.

Compiled by the Department of Health in  collaboration with the Subcommittee for Chemoprophylaxis and Therapy of the National  Malaria Advisory Group.

October 1996